FDA Accepts Sumitomo’s Vibegron Application for Overactive Bladder in Men with BPH Therapy

FDA Accepts Sumitomo’s Vibegron Application for Overactive Bladder in Men with BPH Therapy

Sumitomo Pharma America, Inc. (SMPA) declared a significant development today as the U.S. Food and Drug Administration (FDA) accepted its…